NASDAQ · RYTM
Rhythm Pharmaceuticals, Inc.
Healthcare · Biotechnology
$92.57▼ 0.54% ($0.50)at close
After hours$93.04▲ 0.51%7:30 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 59.9% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
That's below its past 4-year pace of 178.5%.
Value per share
Base case
$6.93
Price used $92.57 is 13.4× this
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
Revenue each value needs
Revenue today $240M. The price needs $26.2B by 2036. Base case: $1.4B. At its recent pace: $6.7T. Bear to Bull: $894M to $2.1B.
Revenue today $240M. The price needs $26.2B by 2036. Base case: $1.4B. At its recent pace: $6.7T. Bear to Bull: $894M to $2.1B.
Revenue in 2036
today $240M
+$24.8Bmore than the Base case · 18.2×
Value per share · Base case
$6.93
Price $92.57
13.4× this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 13.4%
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 17.21% over the last year. Revenue grew 53.51% over the trailing twelve months. Operating margin moved from -113.53% to -83.62%. Free cash flow declined 39.7% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -83.62%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
22
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 3, 2026
Q3 FY26 · EPS est -$0.71 · Revenue est $85.6M
Q2 FY26
Reported Aug 4, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.73
Estimate
-$0.81
Year over year
n/m
Vs prior quarter
n/m
3 beats · 1 miss in the last 4 quarters
Institutional Sentiment
Rhythm Pharmaceuticals, Inc. · RYTM
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.